Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 15/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 6/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.37 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.33 |
| ▸ | GLP1R | P43220 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20285916 | 0.76 | CYP2C19 (0.37) | PTGS2PTGS1NR1H2NR1H3ALDH1A1 | |
| SCHEMBL20303514 | 0.73 | PDE2A (0.42) | ALDH1A1 | |
| SCHEMBL30328009 | 0.72 | TRPV4 (0.40) | PTGS2PTGS1 | |
| SCHEMBL15819839 | 0.71 | PTGS2 (0.37) | PTGS2PTGS1ALDH1A1SMN1; SMN2GLP1R | |
| SCHEMBL31676278 | 0.70 | CYP3A4 (0.34) | PTGS2PTGS1NR1H2NR1H3ALDH1A1 | |
| SCHEMBL20303529 | 0.69 | TRPV3 (0.36) | PTGS2PTGS1ALDH1A1SMN1; SMN2 | |
| SCHEMBL20303701 | 0.69 | NFE2L2 (0.38) | PTGS2PTGS1ALDH1A1SMN1; SMN2 | |
| SCHEMBL24602718 | 0.68 | ALDH1A1 (0.32) | ALDH1A1SMN1; SMN2GLP1R | |
| SCHEMBL20303556 | 0.68 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL20303366 | 0.68 | TRPM8 (0.41) | NR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3558298-B1 | ANTIDIABETIC SPIROCHROMAN COMPOUNDS | MERCK SHARP & DOHME LLC (US) | 2026-03-11 | — | — | EP | disclosed |
| US-10968232-B2 | Antidiabetic spirochroman compounds | MERCK SHARP & DOHME CORP. (US) | 2021-04-06 | — | — | US | disclosed |
| US-20190337961-A1 | ANTIDIABETIC SPIROCHROMAN COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2019-11-07 | — | — | US | disclosed |
| EP-3558298-A1 | ANTIDIABETIC SPIROCHROMAN COMPOUNDS | Merck Sharp & Dohme Corp. (US) | 2019-10-30 | — | — | EP | disclosed |
| WO-2018118670-A1 | ANTIDIABETIC SPIROCHROMAN COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2018-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10968232-B2 | Antidiabetic spirochroman compounds | GPR119, GPR52, GPR55 | PTGS2 1478/4885PTGS1 1530/4885NR1H2 8/4885 |
| US-20190337961-A1 | ANTIDIABETIC SPIROCHROMAN COMPOUNDS | GPR119, GPR52, GPR55 | PTGS2 1478/4885PTGS1 1530/4885NR1H2 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.